Quick Facts / Company Snapshot
- Company Name: Repligen Corporation
- Stock Ticker: NASDAQ: RGEN
- Headquarters: 41 Seyon Street, Bldg. 1, Suite 100, Waltham, Massachusetts 02453
- Year Incorporated: 1981
- Year Public: 1986
- Total Employees: Approximately 2,000
- Total Revenue (2025): $738,256,000
- Product Revenue (2025): $737,960,000
- Net Income (2025): $48,894,000
- Gross Margin (2025): 52.3%
- Outstanding Shares: 56,331,110 (as of February 20, 2026)
- Stockholders of Record: 198 (as of February 20, 2026)
- Chief Executive Officer: Olivier Loeillot
- Chief Financial Officer: Jason K. Garland
- Executive Chair of the Board: Tony J. Hunt
- Total Assets (2025): $2,949,699,000
- Total Liabilities (2025): $843,570,000
- Total Stockholders’ Equity (2025): $2,106,129,000
- R&D Expenses (2025): $54,177,000
- Global Manufacturing Sites: 19
Company Overview
Repligen Corporation operates as a global life sciences company dedicated to developing and commercializing highly innovative bioprocessing technologies and systems. These systems are explicitly designed to increase efficiencies and flexibility in the complex process of manufacturing biological drugs. As the broader market for biologics experiences continued growth and expansion, the company serves as a critical partner for global biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and other life science integrators.
The organization is committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs. The company’s technology supports the manufacturing of monoclonal antibodies (mAbs), mAb derivatives like antibody-drug conjugates, recombinant proteins, RNA-based therapeutics, vaccines, and cell and gene therapies (C>). Repligen currently operates as a single bioprocessing business, offering a comprehensive suite of products that serve both upstream and downstream processes in biological drug manufacturing.
The company has built its foundation on over 40 years of industry expertise. This deep experience has allowed the organization to develop a broad and diversified product portfolio reflecting a passion for innovation and a customer-first culture. To maintain its competitive edge, the company capitalizes on opportunities to maximize the value of its product platform through organic growth initiatives, such as internal innovation and commercial leverage, alongside targeted acquisitions.
- Primary customers face critical pressures regarding production costs, capacity, quality, and time, which Repligen’s products are built to address.
- The company helps set new standards for the way biologics are manufactured across the globe.
- A majority of the company’s revenue is derived from consumable and single-campaign (single-use) product sales.
- Hardware and equipment offerings have grown in recent years, complementing the consumable product lines.
- Products offer customization, scalability, plug-and-play convenience, and closed-system technologies to mitigate contamination risks.
Business Segments
Repligen operates and manages its business as one reportable segment and one reporting unit. However, its revenue is generated through distinct product franchises. The total revenue for the year ended December 31, 2025, was $738,256,000. Below is the breakdown of the product franchises sorted by revenue, along with their calculated percentage of the total revenue.
Filtration Products
- Revenue (2025): $402,792,000
- Percentage of Total Revenue: 54.56% (Calculated from $402,792,000 / $738,256,000)
Filtration represents the company’s largest franchise and features the broadest product offering covering both upstream and downstream technologies. The franchise generates revenue through the sale of filtration systems, flat sheet cassettes, filters, membranes, modules, and other related consumables. These systems are utilized in the filtration, isolation, purification, and concentration of biologics and diagnostic products. The company also markets controllers, which are advanced filtration devices used in upstream processes to continuously remove cellular metabolic waste. This process frees healthy cells to continue producing the biologic drug of interest.
Chromatography Products
- Revenue (2025): $153,176,000
- Percentage of Total Revenue: 20.75% (Calculated from $153,176,000 / $738,256,000)
The chromatography franchise includes products used in downstream purification, development, manufacturing, and quality control of biological drugs. The majority of the revenue in this category relates to the pre-packed chromatography column product line. Each column is delivered pre-packaged with the customer’s choice of chromatography resin. The resin can either be provided by the company on behalf of the customer or supplied directly by the customer. This franchise also includes state-of-the-art, configurable chromatography systems that integrate various hardware, components, and consumable products to simplify bioprocessing operations.
Proteins Products
- Revenue (2025): $97,435,000
- Percentage of Total Revenue: 13.20% (Calculated from $97,435,000 / $738,256,000)
The proteins franchise generates revenue primarily through the sale of affinity protein ligands, resins, and cell culture growth factors. The company manufactures multiple forms of protein ligands under long-term supply agreements with major life sciences companies. These life sciences companies subsequently sell their chromatography media to end-users, such as biopharmaceutical manufacturers. Furthermore, the company manufactures growth factors for sale under long-term supply agreements and for direct sales to its customers. These products encourage greater cell growth and maximize overall output from bioreactors.
Process Analytics Products
- Revenue (2025): $81,237,000
- Percentage of Total Revenue: 11.00% (Calculated from $81,237,000 / $738,256,000)
This franchise offers both downstream and upstream process analytical technology (PAT) solutions. The downstream portfolio was established through the acquisition of C Technologies, Inc. in 2019, while the upstream solutions were added through the acquisition of the 908 Devices PAT Portfolio in 2025. Rebranded as PATsmart in 2025, the offerings include the sale of systems, consumables, and services. These products complement and support the company’s existing franchises by offering end-users real-time analytics. The slope spectroscopy systems deliver multiple process benefits, including the elimination of manual dilutions and rapid time to results.
Other Products
- Revenue (2025): $3,320,000
- Percentage of Total Revenue: 0.45% (Calculated from $3,320,000 / $738,256,000)
This category captures the remaining product sales that fall outside the four primary franchises. It represents a minor portion of the company’s overall product portfolio.
Royalty and Other Revenue
- Revenue (2025): $296,000
- Percentage of Total Revenue: 0.04% (Calculated from $296,000 / $738,256,000)
Royalty and other revenue relate to royalties received from a third-party systems manufacturer associated with the OPUS chromatography columns. These royalty revenues are variable and are completely dependent on the sales generated by the company’s partners.
History and Evolution
Repligen Corporation was incorporated in Delaware in 1981 and became a publicly traded company in 1986. Over its history, the company has transformed into a leader in bioprocessing innovation through a mix of internal research and targeted strategic acquisitions. Since 2012, the company has completed 15 acquisitions across its four franchises, building a substantial base of technology assets. The acquisition strategy is focused on identifying differentiated technology while considering the potential for integration with internally developed technologies.
A major strategic shift has occurred in the company’s commercial approach. The organization is transitioning from selling individual products to offering its broad portfolio as integrated solutions. These integrated solutions are designed to support entire unit operations, manage fluids between unit operations, and provide in-line advanced analytics. This shift allows the company to connect upstream filtration systems directly to downstream chromatography and purification systems.
- September 2021: The company completed the strategic acquisition of Avitide, Inc., a market leader in affinity ligand discovery and development, marking a major step forward for the Proteins franchise.
- April 2023: Acquired FlexBiosys, Inc., expanding the fluid management portfolio with custom manufacturing of single-use bioprocessing products.
- October 2023: Acquired Metenova Holding AB, adding magnetic mixing and drive train technologies to the fluid management portfolio.
- December 2024: Acquired Tantti Laboratory Inc., accelerating the expansion into new modality markets with scalable purification solutions, specifically through the introduction of HiPer base beads for larger molecule biologics.
- March 2025: Completed the acquisition of 908 Devices Inc.’s desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications, strengthening the upstream PAT solutions.
Products and Services
The company’s product portfolio is highly diversified and grouped into distinct franchises. Revenue is recognized when control of the promised products or services is transferred to customers. Below is the detailed breakdown of products within the respective franchises.
Filtration Products Portfolio
- XCell ATF Cell Retention Systems: Used in upstream bioprocessing for perfusion applications to improve volumetric productivity. The system enables continuous cell culture, retaining cells in the bioreactor while fresh nutrients are fed and waste is removed. This allows cell densities to reach two to three times higher than standard fed-batch cultures, increasing product yield and facility utilization. Available in sizes scaling from laboratory to 5,000-liter production bioreactors.
- Flat Sheet Cassettes: The TangenX product portfolio includes flat sheet tangential flow filtration (TFF) cassettes used in downstream ultrafiltration processes like biologic drug concentration and buffer exchange. Includes the single-use SIUS line, the reusable PRO line, and the TangenX SC Device, which is the industry’s first holder-free, self-contained TFF device.
- Hollow Fiber Consumables: Offers a wide range of hollow fiber filters across sizes, surface areas, and membrane chemistries. These filters facilitate easy scale-up from process development to commercial production and are gentle on shear-sensitive products.
- KrosFlo TFF Systems: Designed for scalability from research to commercial manufacturing volumes. These systems offer flexibility between hollow fiber and flat sheet cassette formats. The KrosFlo RS platform features pre-assembled flow kits for error-free installation and includes fully automated GMP compliant models ranging from the benchtop RS10 to the production scale RS50.
- Fluid Management Solutions: A comprehensive portfolio resulting from various acquisitions, including Metenova and FlexBiosys. Products include bags, tubing, valves, totes, carts, and mixers. In 2025, the company launched the ProConnex MixOne RG-X, a novel single-use mixer.
Chromatography Products Portfolio
- OPUS Pre-Packed Columns (PPC): Disposable, single-use or campaign-use columns that replace customer self-packed glass or stainless steel columns for downstream purification. They are delivered sealed and pre-packed with the customer’s choice of resin. The platform includes RoboColumn, MiniChrom, and ValiChrom formats for process development, and larger formats (2.5-80cm inner diameter) for clinical and commercial manufacturing, including the OPUS 80R.
- KRM Chromatography Systems: Acquired through ARTESYN in 2020, these are state-of-the-art, configurable systems engineered for high product recovery and high bioactivity. They feature closed single-use flow paths, over-molded connectors, and process-enabled analytics technology.
- ELISA Test Kits: Used by quality control departments to detect and measure the presence of leached Protein A, other affinity ligands, or growth factors in final biologic products.
Process Analytics (PATsmart) Products Portfolio
- SoloVPE & SoloVPE PLUS Systems: Downstream slope spectroscopy systems used for offline and at-line absorbance measurements for protein concentration determination. The SoloVPE PLUS System, launched in 2025, offers enhanced accuracy, speed, and ease-of-use for complex biological production workflows.
- FlowVPX System: The next-generation FlowVPE designed to meet strict GMP requirements. It offers reliable real-time results for concentration measurements during the GMP manufacturing of biologics.
- Upstream PAT Devices (908 Devices Portfolio): Includes the PATsmart MAVERICK and MAVEN for real-time monitoring of critical bioprocess parameters, the PATsmart REBEL (an at-line cell culture media analyzer), and the PATsmart ZipChip (a high-resolution sample separations device).
Proteins Products Portfolio
- Protein A Affinity Ligands: The essential binding component of Protein A affinity chromatography resins used to purify virtually all mAb-based drugs. The company manufactures these under long-term supply agreements. Through a collaboration with Navigo, Repligen exclusively supplies the NGL-Impact A and NGL-Impact HipH ligands to Purolite.
- AVIPure Resins for New Modalities: Originating from the Avitide and Tantti acquisitions, these affinity resin solutions cater to cell and gene therapies. Products include AVIPure dsRNA, AVIPure HiPerMAAV9, AVIPure HiPerMAAV8, and HiPerMQA, which utilize new HiPer base beads designed for larger molecules.
- Cell Culture Growth Factors: Additives used to maximize output from bioreactors. Products include LONG R3 IGF-1, an insulin-like growth factor that is up to 200 times more potent than standard insulin, and LONG EGF, a recombinant analogue of human epidermal growth factor.
Brand Portfolio
Repligen manages a comprehensive and legally protected portfolio of brands. The company procures and maintains trademark registrations globally for various product brands and services to ensure continued protection in strategic territories. The company actively enforces trademark usage guidelines to prevent unauthorized use.
- Corporate Housemarks: Repligen, the stylized “R” logo, Spectrum, TangenX, Polymem, Metenova, and Tantti.
- Filtration Brands: XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, RPM, and Metenova MixOne.
- Chromatography Brands: OPUS.
- Process Analytics Brands: PATsmart, SoloVPE, FlowVPE, FlowVPX, MAVERICK, MAVEN, REBEL, and ZipChip.
- Proteins Brands: NGL-Impact, AVIPure, and LONG.
Geographical Presence
Repligen operates on a global basis with offices and activities spanning North America, Europe, and the Asia Pacific regions. The company’s operations and sales outside of the United States have increased significantly due to strategic acquisitions and the expansion of its commercial organization. The global commercial organization consists of approximately 390 employees. Geographically, about 200 members of the commercial team are located in North America, 110 are in Europe, and 80 are in the Asia-Pacific (APAC) regions.
North America
- Percentage of Total Revenue (2025): 49%
- Percentage of Total Revenue (2024): 50%
- Percentage of Total Revenue (2023): 44%
- Asset Value (2025): $2,340,178,000
- Long-Lived Asset Value (2025): $257,408,000
North America remains the largest revenue-generating region for Repligen. The United States serves as the core operational hub, hosting the global headquarters in Waltham, Massachusetts. A majority of the company’s 19 manufacturing sites are located in the United States, spanning California, Massachusetts, New Hampshire, New Jersey, and New York. The United States is the only single country that accounted for more than 10% of total revenues during 2025, 2024, and 2023.
Europe
- Percentage of Total Revenue (2025): 34%
- Percentage of Total Revenue (2024): 34%
- Percentage of Total Revenue (2023): 36%
- Asset Value (2025): $489,927,000
- Long-Lived Asset Value (2025): $47,393,000
Europe is a critical market and manufacturing base for the company. Repligen maintains manufacturing sites in Estonia, France, Germany, Ireland, the Netherlands, and Sweden. Notable facilities include the site in Lund, Sweden, where native Protein A ligands and growth factor products are manufactured, and the site in Breda, the Netherlands, which serves as a primary chromatography assembly center. The region is supported by approximately 110 commercial team members.
Asia Pacific (APAC) & Rest of World
- Percentage of Total Revenue (2025): 17%
- Percentage of Total Revenue (2024): 16%
- Percentage of Total Revenue (2023): 20%
- Asset Value (2025 APAC): $119,594,000
- Long-Lived Asset Value (2025 APAC): $6,264,000
The Asia Pacific region, combined with the rest of the world (consisting of Central and South America and Africa), represents a growing geographic segment. The company has offices and activities in Japan, South Korea, China, India, and Taiwan. The recent acquisition of Tantti Laboratory Inc. expanded the company’s footprint in Taoyuan City, Taiwan. The company is actively investing in the APAC region to increase its commercial presence by selectively building its team, which currently consists of around 80 commercial employees.
Profit and Loss
The following table details the company’s consolidated statements of comprehensive income (loss) for the years ended December 31, 2025, 2024, and 2023.
| Item (Amounts in thousands, except per share data) | 2025 | 2024 | 2023 |
| Revenue: | |||
| Product | $737,960 | $634,178 | $631,979 |
| Royalty and other revenue | $296 | $261 | $383 |
| Total revenue | $738,256 | $634,439 | $632,362 |
| Costs and operating expenses: | |||
| Cost of goods sold | $352,011 | $359,794 | $353,922 |
| Research and development | $54,177 | $43,200 | $42,722 |
| Selling, general and administrative | $290,508 | $263,368 | $218,584 |
| Change in fair value of contingent consideration | $(13,607) | $3,191 | $(30,569) |
| Total costs and operating expenses | $683,089 | $669,553 | $584,659 |
| Income (loss) from operations | $55,167 | $(35,114) | $47,703 |
| Other income (expense), net: | |||
| Investment income | $27,574 | $35,827 | $24,135 |
| Interest expense | $(21,513) | $(20,731) | $(2,503) |
| Loss on extinguishment of debt | $0 | $0 | $(12,676) |
| Amortization of debt issuance costs | $(1,660) | $(1,843) | $(8,075) |
| Other income (expense), net | $2,815 | $(5,174) | $8,123 |
| Other income, net | $7,216 | $8,079 | $9,004 |
| Income (loss) before income taxes | $62,383 | $(27,035) | $56,707 |
| Income tax provision (benefit) | $13,489 | $(1,521) | $21,111 |
| Net income (loss) | $48,894 | $(25,514) | $35,596 |
| Earnings (loss) per share: | |||
| Basic | $0.87 | $(0.46) | $0.64 |
| Diluted | $0.86 | $(0.46) | $0.63 |
Balance Sheet
The following table presents the consolidated balance sheets as of December 31, 2025, and December 31, 2024.
| Assets (Amounts in thousands) | 2025 | 2024 |
| Current assets: | ||
| Cash and cash equivalents | $566,021 | $757,355 |
| Marketable securities | $201,607 | $0 |
| Accounts receivable, net | $158,587 | $134,115 |
| Inventories, net | $170,458 | $142,964 |
| Prepaid expenses and other current assets | $40,712 | $31,607 |
| Total current assets | $1,137,385 | $1,066,041 |
| Noncurrent assets: | ||
| Property, plant and equipment, net | $186,614 | $197,738 |
| Intangible assets, net | $386,147 | $397,897 |
| Goodwill | $1,114,408 | $1,030,995 |
| Deferred tax assets | $694 | $749 |
| Operating lease right of use assets | $119,538 | $135,378 |
| Other noncurrent assets | $4,913 | $868 |
| Total noncurrent assets | $1,812,314 | $1,763,625 |
| Total assets | $2,949,699 | $2,829,666 |
| Liabilities and Stockholders’ Equity (Amounts in thousands) | 2025 | 2024 |
| Current liabilities: | ||
| Accounts payable | $30,010 | $32,134 |
| Operating lease liabilities | $21,559 | $15,104 |
| Contingent consideration | $5,049 | $17,126 |
| Accrued liabilities | $79,208 | $62,423 |
| Total current liabilities | $135,826 | $126,787 |
| Noncurrent liabilities: | ||
| Convertible Senior Notes due 2028, net | $542,213 | $525,567 |
| Deferred tax liabilities | $22,496 | $22,775 |
| Noncurrent operating lease liabilities | $126,176 | $145,576 |
| Noncurrent contingent consideration | $1,304 | $19,662 |
| Other noncurrent liabilities | $15,555 | $16,581 |
| Total noncurrent liabilities | $707,744 | $730,161 |
| Total liabilities | $843,570 | $856,948 |
| Stockholders’ equity: | ||
| Preferred stock | $0 | $0 |
| Common stock | $563 | $561 |
| Additional paid-in capital | $1,651,849 | $1,617,336 |
| Accumulated other comprehensive loss | $(2,531) | $(52,533) |
| Retained earnings | $456,248 | $407,354 |
| Total stockholders’ equity | $2,106,129 | $1,972,718 |
| Total liabilities and stockholders’ equity | $2,949,699 | $2,829,666 |
Cash Flow
The following table details the company’s consolidated statements of cash flows for the years ended December 31, 2025, 2024, and 2023.
| Item (Amounts in thousands) | 2025 | 2024 | 2023 |
| Net income (loss) | $48,894 | $(25,514) | $35,596 |
| Total cash provided by operating activities | $117,417 | $175,394 | $113,918 |
| Cash flows for investing activities: | |||
| Acquisitions, net of cash acquired | $(70,328) | $(54,765) | $(186,642) |
| Purchases of marketable securities | $(200,257) | $0 | $0 |
| Maturities of marketable securities | $0 | $0 | $102,323 |
| Additions to capitalized software costs | $(2,211) | $(4,222) | $(2,766) |
| Purchases of property, plant and equipment | $(23,519) | $(25,677) | $(36,222) |
| Sale of property, plant and equipment | $238 | $0 | $0 |
| Purchase of intellectual property | $0 | $(3,006) | $0 |
| Other investing activities | $(2,397) | $1,287 | $32 |
| Total cash used in investing activities | $(298,474) | $(86,383) | $(123,275) |
| Cash flows (for) from financing activities: | |||
| Repurchase of common stock | $0 | $0 | $(14,386) |
| Proceeds from issuance of 2023 Notes | $0 | $0 | $290,094 |
| Proceeds from exercise of stock options | $3,176 | $4,294 | $1,076 |
| Payment of debt issuance costs | $0 | $0 | $(7,253) |
| Payment of tax withholding obligation on vesting of restricted stock | $(8,833) | $(9,882) | $(13,227) |
| Repayment of 2019 Notes | $0 | $(69,939) | $0 |
| Payment of earnout consideration | $(9,548) | $(7,375) | $(7,298) |
| Other financing activities | $0 | $0 | $(45) |
| Total cash (used in) provided by financing activities | $(15,205) | $(82,902) | $248,961 |
| Effect of exchange rate changes on cash and cash equivalents | $4,928 | $(77) | $(11,739) |
| Net (decrease) increase in cash and cash equivalents | $(191,334) | $6,032 | $227,865 |
| Cash and cash equivalents, beginning of period | $757,355 | $751,323 | $523,458 |
| Cash and cash equivalents, end of period | $566,021 | $757,355 | $751,323 |
Board of Directors and Leadership Team
The company is guided by a highly experienced leadership team and Board of Directors responsible for strategy, risk management, and overall governance. The Board exercises its oversight function through various committees, including the Audit Committee, which directly oversees the management of risk exposure across areas like data security and sustainability.
- Olivier Loeillot: Chief Executive Officer and Director (Principal Executive Officer).
- Jason K. Garland: Chief Financial Officer (Principal Financial Officer).
- Violetta Hughes: Chief Accounting Officer (Principal Accounting Officer).
- Tony J. Hunt: Executive Chair of the Board. (Note: Mr. Hunt relinquished his position as CEO effective September 1, 2024, transitioning to Executive Chair. On January 6, 2026, it was announced he will retire as a member of the Board effective March 13, 2026, but will remain an advisor ).
- Karen A. Dawes: Lead Independent Director.
- Nicolas M. Barthelemy: Director.
- Carrie Eglinton Manner: Director.
- Konstantin Konstantinov: Director.
- Martin D. Madaus: Director.
- Rohin Mhatre: Director.
- Glenn P. Muir: Director.
- Margaret A. Pax: Director.
Subsidiaries, Associates, Joint Ventures
Repligen operates globally through a vast network of wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in the consolidated financial statements. The company has not explicitly disclosed the individual revenue contributions or ownership percentages (beyond implying wholly-owned status for its consolidated entities) of these subsidiaries.
The legal entities representing the company’s global footprint include:
- Spectrum Life Sciences, LLC (United States)
- Repligen (Shanghai) Biotechnology Co. Ltd. (China)
- Repligen Estonia OṺ (Estonia)
- Polymem S.A. (France)
- Repligen GmbH (Germany)
- 908 Devices GmbH (Germany)
- Repligen India Private Limited (India)
- ARTeSYN Biosolutions Holdings Ireland Ltd. (Ireland)
- ARTeSYN Biosolutions Ireland Limited (Ireland)
- Repligen Ireland Limited (Ireland)
- Repligen Japan LLC (Japan)
- Repligen Europe B.V. (Netherlands)
- Repligen Singapore Pte. Ltd. (Singapore)
- Repligen Korea Co., Ltd. (South Korea)
- Repligen Sweden AB (Sweden)
- Tantti Laboratory Inc (Taiwan)
- Repligen UK Limited (United Kingdom)
Other Investments (Including Minority / Portfolio Holdings)
The company holds specific investments categorized as marketable securities, which are managed in accordance with an investment policy designed to preserve principal and maintain liquidity.
- Marketable Securities (U.S. Treasury Bills): The company holds $201,607,000 in short-term U.S. Treasury bills as of December 31, 2025.
- Investment Strategy: These securities are classified as available-for-sale investments and mature within one year from the balance sheet date.
- Fair Value: The amortized cost of these bills is $201,554,000, with gross unrealized gains of $55,000 and gross unrealized losses of $2,000, resulting in the estimated fair value of $201,607,000. This is a Level 2 fair value measurement.
- Risk Profile: The company limits its investments to highly-rated securities to mitigate credit loss risks. A hypothetical 100 basis point increase in interest rates would have no effect on the cash position due to the short-term maturity periods.
Physical Properties
Repligen maintains a global footprint of offices, manufacturing sites, and warehouses to support its operations. The company owns or leases material properties across the globe.
| Location | Square Feet | Principal Use | Lease Expiration |
| Waltham, Massachusetts | 182,243 | Corporate headquarters, manufacturing, research and development, marketing and administrative offices | 31-Oct-30 |
| Rancho Dominguez, California | 126,267 | Manufacturing, research and development, marketing and administrative operations | 15-Jul-35 |
| Shrewsbury, Massachusetts | 138,969 | Warehouse | 31-Jan-34 |
| Marlborough, Massachusetts | 130,700 | Manufacturing operations | 30-Nov-33 |
| Toulouse, France | 79,868 | Manufacturing and administrative operations | 31-Mar-32 |
| Jüri, Estonia | 75,726 | Office, manufacturing and storage space | 13-Mar-34 |
| Lund, Sweden | 65,240 | Manufacturing and administrative operations | 31-Dec-26 |
| Hopkinton, Massachusetts | 64,000 | Manufacturing, assembly site | 13-Jul-34 |
| Bridgewater, New Jersey | 57,739 | Manufacturing and administrative operations | 30-Nov-34 |
| Waterford, Ireland | 41,928 | Manufacturing, administrative operations and assembly site | 19-May-34 |
| Clifton Park, New York | 34,386 | Manufacturing operations | 30-Nov-29 |
| Lebanon, New Hampshire | 31,313 | Research and development and administrative operations | 31-Jul-26 |
Founders
Repligen was incorporated in Delaware in 1981. The official filings do not specifically highlight individual founding figures by name, focusing instead on the company’s long-standing corporate history and evolution over its 40-plus years of industry expertise.
Investments and Capital Expenditure Plans
The company continually invests in its operations to support capacity expansions, technological advancements, and research and development.
- Capital Expenditures: In 2025, capital expenditures consumed $25.7 million. This figure is inclusive of $2.2 million in capitalized costs related to internal-use software. By comparison, capital expenditures in 2024 consumed $29.9 million.
- Research and Development (R&D): The company actively funds R&D to develop new high-value bioprocessing products. In 2025, R&D expenses increased to $54.2 million, up 25.4% from $43.2 million in 2024. This increase was primarily driven by the acquisitions of the 908 Devices PAT Portfolio and Tantti.
- Future Capital Requirements: The company expects operating expenses to increase in 2026 as it expands its bioprocessing business. Future capital requirements will depend on the scope of R&D activities, the expansion of commercial capabilities, potential acquisitions, and investments in the intellectual property portfolio.
- Strategic Transactions: Repligen actively evaluates various strategic transactions on an ongoing basis, including licensing or acquiring complementary products, technologies, or businesses. Should the company pursue large-scale acquisitions, it may seek additional financing through equity sales, convertible debt securities, or credit facilities.
Shareholding Pattern
Repligen’s common stock trades on the Nasdaq Global Select Market under the symbol “RGEN”. The company has a diverse base of institutional and public shareholders.
- Outstanding Shares: As of February 20, 2026, there were 56,331,110 shares of common stock outstanding.
- Stockholders of Record: The company had 198 stockholders of record as of February 20, 2026.
- Market Value: The aggregate market value of voting and non-voting common equity held by non-affiliates as of June 30, 2025, was approximately $6.0 billion.
- Share Repurchase Programs: In December 2023, the Board authorized a stock repurchase program of up to $25.0 million. During 2025 and 2024, the company did not repurchase any shares under this specific program, though it had utilized $14.4 million in 2023 to offset dilution from the issuance of its 2023 Notes.
- Dividends: The company has not paid any dividends since its inception and does not intend to pay dividends in the foreseeable future, choosing instead to retain earnings to support operations.
Future Strategy
Repligen’s future strategy is built on a foundation of technology leadership, deep customer relationships, and continuous operational improvement. The management team intends to build on the history of delivering strong financial performance through five key pillars:
- Continued Innovation: The company plans to capitalize on internal technological expertise to develop products addressing unmet needs in bioprocessing. They are investing in platform and derivative products to support all franchises, with a specific aim to provide customers with integrated, more automated, and efficient manufacturing processes.
- Increasing Market Position: The company aims to grow within existing markets through cross-selling and geographic expansion. A key accounts team is specifically focused on penetrating large pharmaceutical and CDMO accounts, increasing both the number of product lines purchased and overall volume.
- Leveraging Product Mix: The company recognizes an opportunity to index higher to commercial volumes. As customers progress through clinical trials to commercialization, product volumes naturally increase. Furthermore, Repligen’s products are well-suited for new modality applications, representing a growing portion of customer pipelines.
- Targeted Acquisitions: Management will selectively pursue acquisitions of innovative technologies and products that address specific customer pain points. These targets must be complementary to the existing portfolio or help serve customers across different modalities.
- Operational Efficiency: The company seeks to expand operating margins through volume leverage, manufacturing productivity, and operating expense discipline. Investments in information technology modernization will support global operations and optimize resources across the company’s footprint.
Key Strengths
Repligen’s competitive advantage is rooted in its specialized product offerings and its ability to scale alongside its customers’ needs.
- Comprehensive Suite of Products: The company offers highly differentiated technologies that span both upstream and downstream unit operations in biological drug manufacturing.
- History of Disruptive Innovation: Repligen is recognized as an innovation leader, consistently introducing products that solve specific, complex bioprocessing challenges.
- Market-Leading Formats: Products like the OPUS Pre-Packed Columns provide immediate plug-and-play convenience, significantly reducing labor, equipment, and facility requirements for customers while delivering cost savings.
- Strategic Value Add: The integration of real-time process monitoring, such as the KrosFlo KR2i RPM coupled with FlowVPX technology, allows customers to benefit from improved process control and reduced process risk.
- Robust Quality Systems: Key manufacturing facilities hold ISO 9001:2015 certifications, maintaining strict process control, traceability, and product conformance. The company also utilizes the Repligen Performance System (RPS) to continuously improve operational performance, resulting in productivity savings and manufacturing scrap reductions.
Key Challenges and Risks
Operating in the highly complex and heavily regulated life sciences sector presents numerous risks that could materially harm the business, financial condition, or results of operations.
- Intense Competition: The bioprocessing market is highly competitive and subject to rapid change. Competitors include large, well-capitalized entities like Danaher Corporation (Cytiva), Thermo Fisher Scientific, MilliporeSigma, and Sartorius. These competitors may spend more aggressively on R&D and marketing or bundle products to offer lower prices.
- Supply Chain Vulnerabilities: Repligen relies on a limited number of suppliers—and in some cases, a single supplier—for critical materials. For instance, only a small number of suppliers are qualified to supply materials for the XCell ATF systems. Transitioning to alternative suppliers would be time-consuming and expensive.
- Customer Concentration: While no single customer currently represents more than 10% of total revenues, the loss of, or reduction in orders from, any large customer would significantly reduce revenues.
- Acquisition Integration Risks: The strategy of growth through acquisition involves significant operational, financial, and managerial challenges. Risks include difficulties in integrating new technologies, underperformance relative to expectations, and the potential impairment of intangible assets and goodwill.
- Internal Control Weaknesses: The company identified material weaknesses in its internal control over financial reporting as of December 31, 2025. These weaknesses pertained to IT general controls and business process-level controls related to inventory valuation and the financial statement close process. While efforts are underway to remediate these issues, failure to do so could adversely affect the company’s ability to report financial information accurately.
- Cybersecurity Threats: Internal computer systems are vulnerable to cyber-attacks, ransomware, and unauthorized access. The company experienced a security incident in 2024, highlighting the persistent risk of data compromises that could disrupt operations or damage the company’s reputation.
- Debt Servicing Obligations: In December 2023, the company incurred significant indebtedness by issuing $600.0 million in Convertible Senior Notes due 2028. Servicing this debt requires significant cash flow, and failure to meet these obligations could limit operational flexibility.
Conclusion and Strategic Outlook
Repligen Corporation demonstrated strong financial resilience and growth in the fiscal year 2025, reporting a total revenue of $738.3 million and successfully returning to profitability with a net income of $48.9 million. The company’s 16.4% year-over-year product revenue growth illustrates the widespread acceptance of its portfolio across the filtration, chromatography, process analytics, and proteins franchises.
Looking ahead, Repligen is uniquely positioned to capture value from the expanding biologics market, particularly in the rapidly growing field of new modalities such as cell and gene therapies. By shifting its commercial approach toward offering integrated solutions rather than isolated products, the company is deeply embedding itself into the manufacturing workflows of the world’s leading biopharmaceutical companies. While the company must navigate the challenges of intense market competition, supply chain constraints, and internal control remediations, its commitment to disruptive innovation, targeted acquisitions—such as the 908 Devices PAT Portfolio and Tantti—and rigorous operational efficiency provides a clear roadmap for sustained long-term growth and market leadership.
FAQ Section
What is Repligen Corporation’s primary business focus? Repligen is a global life sciences company that develops and commercializes innovative bioprocessing technologies and systems used to increase efficiency and flexibility in the manufacturing of biological drugs, such as monoclonal antibodies and cell and gene therapies.
How much revenue did Repligen generate in 2025? For the fiscal year ended December 31, 2025, Repligen reported a total revenue of $738.3 million, representing a 16.4% increase compared to the previous year.
What is Repligen’s largest product franchise? Filtration is the company’s largest franchise, generating $402.8 million in 2025, which accounted for approximately 54.56% of total revenue.
Has Repligen made any recent acquisitions? Yes, Repligen maintains an active acquisition strategy. Recent notable acquisitions include the 908 Devices PAT Portfolio in March 2025, Tantti Laboratory Inc. in December 2024, Metenova Holding AB in October 2023, and FlexBiosys, Inc. in April 2023.
Where are Repligen’s global headquarters located? The company’s global corporate headquarters are located at 41 Seyon Street, Waltham, Massachusetts, in the United States.
What are the OPUS Pre-Packed Columns? OPUS Pre-Packed Columns are a core product in the Chromatography franchise. They are disposable, single-use columns delivered pre-packed with the customer’s choice of resin, designed to replace traditional self-packed glass or stainless steel columns for downstream purification.
Does Repligen pay dividends to its shareholders? No, the company has not paid any dividends since its inception and does not intend to pay any dividends in the foreseeable future, preferring to retain earnings to support and grow operations.
What were the company’s research and development expenses in 2025? In 2025, Repligen spent $54.2 million on research and development, an increase of 25.4% from 2024, primarily driven by the integration of newly acquired technologies.
Official Site: repligen.com
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
